GRAIL (NASDAQ:GRAL) Shares Down 4% After Insider Selling

GRAIL, Inc. (NASDAQ:GRAL) shares fell 4% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $60.02 and last traded at $62.95. 494,947 shares traded hands during mid-day trading, a decline of 61% from the average session volume of 1,277,161 shares. The stock had previously closed at $65.55.

Specifically, President Joshua J. Ofman sold 9,692 shares of GRAIL stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $64.00, for a total transaction of $620,288.00. Following the sale, the president directly owned 478,182 shares in the company, valued at approximately $30,603,648. This trade represents a 1.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on GRAL shares. UBS Group set a $75.00 target price on GRAIL in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Saturday, September 27th. Finally, Canaccord Genuity Group lifted their price objective on shares of GRAIL from $43.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GRAIL presently has a consensus rating of “Hold” and an average target price of $56.67.

GRAIL Stock Performance

The stock has a market capitalization of $2.22 billion, a PE ratio of -4.71 and a beta of 4.11. The business’s 50-day moving average price is $39.16 and its 200 day moving average price is $37.47.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.14) by ($0.04). The business had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $37.57 million. GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. As a group, equities research analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Institutional Trading of GRAIL

Large investors have recently modified their holdings of the business. Caldwell Sutter Capital Inc. bought a new position in shares of GRAIL in the first quarter worth approximately $28,000. KBC Group NV grew its stake in GRAIL by 187.7% in the 1st quarter. KBC Group NV now owns 1,430 shares of the company’s stock worth $37,000 after buying an additional 933 shares in the last quarter. S.A. Mason LLC increased its holdings in shares of GRAIL by 50.1% in the 1st quarter. S.A. Mason LLC now owns 1,499 shares of the company’s stock worth $38,000 after buying an additional 500 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of GRAIL by 768.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock valued at $42,000 after buying an additional 722 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after acquiring an additional 1,401 shares during the last quarter.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.